| Literature DB >> 16275197 |
Dimitrios N Tziakas1, Georgios K Chalikias, Miltiadis Papaioakeim, Eleni I Hatzinikolaou, Dimitrios A Stakos, Ioannis K Tentes, Nikolaos Papanas, Alexandros Kortsaris, Efstratios Maltezos, Dimitrios I Hatseras.
Abstract
It has been reported that circulating matrix metalloproteinase (MMP) levels are upregulated in patients with chronic heart failure. However, experimental studies indicate that differences in the profiles of MMPs and tissue inhibitors of metalloproteinase (TIMPs) may exist in ischemic compared with nonischemic cardiomyopathy. This study examined whether circulating levels of MMPs and TIMP-1 are related to the pathogenesis of heart failure. Circulating levels of MMP-2, MMP-3, and TIMP-1 were assessed in 52 patients with compensated end-stage chronic heart failure, including 26 patients (mean 64 +/- 7 years; 10 men) with ischemic cardiomyopathy (IC) and 26 (mean age 66 +/- 6 years; 14 men) with idiopathic dilated cardiomyopathy (IDC). Serum MMP-2 (p <0.001) and MMP-3 (p <0.001) levels were higher in patients with IDC than in those with IC. Serum TIMP-1 levels were lower in patients with IDC (p = 0.011) than in those with IC. This study shows that in patients with compensated end-stage chronic heart failure, circulating levels of MMP-2, MMP-3, and TIMP-1 are associated with the pathogenesis of heart failure.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16275197 DOI： 10.1016/j.amjcard.2005.06.096
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778